Format

Send to:

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2009 Oct;10(10):975-80. doi: 10.1016/S1470-2045(09)70227-X.

Development of therapeutic HPV vaccines.

Author information

  • 1Johns Hopkins University Hospital, Baltimore, MD, USA. ctrimbl@jhmi.edu

Abstract

At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

PMID:
19796749
[PubMed - indexed for MEDLINE]
PMCID:
PMC3090037
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk